We found that BTKi treatment led to a reduction of NFATc1 mRNA levels (Supplementary Fig. 8C) and protein levels in some of the CLL samples (Fig. 4B and Supplementary 8A). This evidence concerns the gene IBTK and B-cell chronic lymphocytic leukemia.